Last reviewed · How we verify
methyl prednisolone acetate
Methylprednisolone acetate is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone acetate is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus), Allergic reactions and dermatological conditions, Asthma and chronic obstructive pulmonary disease exacerbations.
At a glance
| Generic name | methyl prednisolone acetate |
|---|---|
| Also known as | Depo-Medrol, steroid |
| Sponsor | Benazir Bhutto Hospital, Rawalpindi |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone acetate is a long-acting corticosteroid ester that penetrates cell membranes and binds to intracellular glucocorticoid receptors. This binding translocates the receptor to the nucleus, where it modulates gene transcription to decrease production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppress T-cell and B-cell function. The acetate ester formulation provides sustained release, making it suitable for depot injection.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus)
- Allergic reactions and dermatological conditions
- Asthma and chronic obstructive pulmonary disease exacerbations
- Adrenocortical insufficiency
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis (with chronic use)
- Immunosuppression and increased infection risk
- Cushingoid features (with prolonged use)
- Insomnia and mood changes
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Comparing Methylprednisolone And Hyaluronic Acid To Reduce Wisdom Tooth Surgery Complications (PHASE3)
- Tazemetostat Plus CHOP in 1L T-cell Lymphoma (PHASE2)
- Methylprednisolone vs Dexamethasone Interaction With Sugammadex in Pediatric Patients (NA)
- Therapeutic Effect of Shoulder Anterior Capsular Block Versus Suprascapular Nerve Block in Patients With Frozen Shoulder (NA)
- Comparison of Thread Technique Versus Aspiration Plus Steroid Injection for Wrist Ganglion Recurrence (PHASE1, PHASE2)
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methyl prednisolone acetate CI brief — competitive landscape report
- methyl prednisolone acetate updates RSS · CI watch RSS
- Benazir Bhutto Hospital, Rawalpindi portfolio CI